No data are available with regard to human overdosage by accidental or deliberate ingestion of COSOPT.

There have been reports of inadvertent overdosage with timolol maleate ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. The most common signs and symptoms to be expected with overdosage of dorzolamide are electrolyte imbalance, development of an acidotic state, and possibly central nervous system effects.

Treatment should be symptomatic and supportive. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Studies have shown that timolol does not dialyze readily.

COSOPT is contraindicated in patients with:

•     bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease
•     sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock
•     hypersensitivity to any component of this product

The above are based on the components and are not unique to the combination.

Bookmark this page: